Market Place
Sourcing Support
Bain leads $350M bet on oral asthma startup to fund phase 3
12 Jul 2022 //
FIERCEBIOTECH
Knopp Bio Presents New Phase 2 Data at AAAAI 2022 on Oral Dexpramipexole
28 Feb 2022 //
BUSINESSWIRE
Knopp Biosciences` NIH-funded pain program continues to receive the HEAL award
20 Oct 2021 //
BUSINESSWIRE
Knopp Biosciences Announces Positive Results from the Phase 2 EXHALE Trial
08 Sep 2021 //
BUSINESSWIRE
Knopp Biosciences Presents New Phase 2 Data at ERS 2021
07 Sep 2021 //
BUSINESSWIRE
Knopp Biosciences presenteert nieuwe fase 2-gegevens op ERS 2021
07 Sep 2021 //
BUSINESSWIRE
Knopp Reports Results From the Ph2 EXHALE Trial of Oral Dexpramipexole
17 May 2021 //
BUSINESSWIRE
Knopp Biosciences Reports Positive Results From the Phase 2 EXHALE Trial
17 May 2021 //
BUSINESSWIRE
Knopp to Present Details of Positive Results From the Phase 2 EXHALE Trial
13 May 2021 //
BUSINESSWIRE
Knopp meldet positive Top-Line-Ergebnisse aus der Ph-2-Studie EXHALE
14 Jan 2021 //
BUSINESSWIRE
Knopp’s oral asthma drug hits primary endpoint in phase 2
14 Jan 2021 //
FIERCEBIOTECH
Knopp Biosciences NIH-Funded Pain Program Advances to Second Year
08 Oct 2020 //
BUSINESSWIRE
Knopp Biosciences to begin Trial of Oral Dexpramipexole in Eosinophilic Asthma
16 Sep 2020 //
GLOBENEWSWIRE
Knopp Receives Rare Pediatric Disease Designation for Kv7 Activator KB-3061
15 Jul 2020 //
GLOBENEWLSWIRE
Knopp & University of Leicester Update ph2 Trial of Oral Dexpramipexole
02 Dec 2019 //
BUSINESS WIRE
Knopp Biosciences to Present Data Characterizing Its Kv7 Technology Platform
13 Sep 2019 //
BUSINESSWIRE
Knopp begins study of dexpramipexole in eosinophilic asthma patients
20 Aug 2019 //
CLINICALTRIAL SARENA
Knopp Biosciences Announces Start of Ph2 Clinical Evaluating Oral Dexpramipexole
19 Aug 2019 //
BUSINESSWIRE
Knopp Biosciences Presents +ve Preclinical Data for Lead Neonatal Epilepsy Drug
24 May 2019 //
BUSINESSWIRE
Knopp Biosciences Receives FDA Orphan Drug Designation for Dexpramipexole
24 Apr 2019 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.